FindTrial
Sign In

Validity of soluble CD 14 subtype (presepsin) for the diagnosis and prognosis of sepsis in elderly patient admission to intensive care unit

Validity of soluble CD 14 subtype (presepsin) for the diagnosis and prognosis of sepsis in elderly patient admission to intensive care unit

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018937
Enrollment
Unknown
Registered
2018-10-17
Start date
2018-10-18
Completion date
Unknown
Last updated
2019-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

sepsis group:No
Infection group:No
non-infection group:No

Sponsors

Shanghai Oriental Hospital, Tongji University School of Medicine, Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: Sepsis group: 1. Aged =65 years male and female; 2. Patients in ICU (diagnosed with sepsis or suspected sepsis or severe infection with organ damage patients); 3. Signing of the letter of informed consent. Non-sepsis group: including non-infection patients, patients with infections.

Exclusion criteria

Exclusion criteria: 1. Chronic renal failure (CRF) stage III or more 2. Severe trauma or burns 3. Repeat ICU admissions owing to same pathogeny 4. Refuse to sign informed consent and refuse to provide information.

Design outcomes

Primary

MeasureTime frame
Serum soluble CD 14 subtype (presepsin) level;—

Countries

China

Contacts

Public ContactLi Quan

Shanghai Oriental Hospital, Tongji University School of Medicine, Shanghai

quanligene@126.com+86 13816262446

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026